Full Coverage

Schering-Plough To Initiate Phase III Studies With HCV Protease Inhibitor Boceprevir in...

yahoo.com
May 21, 2008
        
Story Timeline:  197 days

Schering-Plough Corporation , a leader in hepatitis research, today announced that it is initiating two large Phase III studies of boceprevir, its investigational oral hepatitis C protease inhibitor, in patients chronically infected with hepatitis C virus genotype 1. [read full story]                    

Add Comment
Latest article on this story:

Schering Plough Initiates Phase 3 Studies with Experimental Oral HCV Protease Inhibitor...

 pharmiweb.co.uk May 23, 2008
First article on this story:

Schering-Plough To Initiate Phase III Studies With HCV Protease Inhibitor Boceprevir in...

 prnewswire.com May 21, 2008
Selected publications with coverage of this story:
redorbit.com prnewswire.com yahoo.com drugs.com pharmiweb.co.uk
RELATED
Found 2 documents:

Schering-Plough To Initiate Phase III Studies With HCV Protease Inhibitor Boceprevir in...

drugs.com
May 22, 2008
        

KENILWORTH, N.J., May 21, 2008 /PRNewswire-FirstCall/ -- Schering-Plough Corporation , a leader in hepatitis research, today announced that it is initiating two large Phase III studies of boceprevir, its investigational oral hepatitis C... ... KENILWORTH, N.J., May 21,...

Schering-Plough to Initiate Two Phase III Hepatitis Studies

redorbit.com
May 22, 2008
        

Posted on: Thursday, 22 May 2008, 09:01 CDT Schering-Plough has announced that it is initiating two large Phase III studies of boceprevir, its investigational oral hepatitis C protease inhibitor, in patients chronically infected with hepatitis C virus genotype 1. One study will be in previously...